24 January 2018 - Eli Lilly has been given a green light to market Taltz in the European Union as a treatment for psoriatic arthritis.

Taltz (ixekizumab) is an antibody that binds to interleukin-17A, a protein that causes inflammation and plays a role in the development of these conditions.

The drug is administered as an injection, either alone or in combination with a conventional disease-modifying anti-rheumatic drug such as methotrexate.

Read Pharma Times article